8 results about "Sterol ester" patented technology

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

The object of this invention is to provide Labyrinthula microorganisms that have high sterol ester production capacity. [Solution] A Labyrinthull microorganism modified to have reduced or lost activity of sterol 24-C-methyltransferase (SMT1) compared to an unmodified strain, wherein the Labyrinthull microorganism is modified to express a modified diacylglycerol acyltransferase 2C (modified DGAT2C) gene, and the modified diacylglycerol acyltransferase 2C (modified DGAT2C) is modified to have a defect in presumed transmembrane regions 1 to 8 of the presumed transmembrane regions 1 to 12 in diacylglycerol acyltransferase 2C (DGAT2C).

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The present application relates to the technical field of health food and soft capsule preparation, in particular to a kind of full sea-buckthorn oil sterol ester soft capsule and low-temperature homogenization preparation method thereof.The content of the soft capsule is composed of sea-buckthorn seed oil 41.7%, phytosterol 33.3% and sea-buckthorn fruit oil 22% by weight percentage, wherein, sea-buckthorn fruit oil completely replaces soybean oil and chemical synthesis suspending agent, as functional excipient and physical stabilizer, when preparing, high-quality sea-buckthorn oil is extracted at 38±0.5 ℃ subcritical low temperature, and the raw and auxiliary materials are mixed at 38±0.5 ℃ constant temperature;then, pill is pressed at 22-24 ℃ environment, and the accurate temperature difference of 14-16 ℃ is used to stimulate micro-phase rearrangement and viscosity improvement of oil liquid.The present application realizes instantaneous physical homogenization and long-term stable non-layering of content under the condition of zero addition of stabilizer, and realizes efficient comprehensive utilization of sea-buckthorn resources.

This invention discloses a dry chemical reagent for total cholesterol detection, comprising a diffusion layer, a spacer layer, and a reagent layer sequentially overlapped. The diffusion layer includes reflective particles, a binder, a surfactant, cholesterol esterase, and cholesterol oxidase. The reagent layer includes a carrier, horseradish peroxidase, an indicator composition, and a buffer solution. The dry chemical detection reagent of this invention employs a coating method, layering a premixed homogeneous slurry onto a support layer. A spacer layer blocks interlayer interference, and phenolic substances replace photosensitizers as chromogens, combined with a specific ratio of substrate and buffer system. The multi-layered, spacer-free, low-interference vertical detection system constructed by this invention significantly improves the repeatability, accuracy, and stability of the detection reagent.

The present application relates to a kind of low-density extracellular vesicles and its preparation method and application, the low-density extracellular vesicles is derived from CD4 + Chimeric antigen receptor T (CD4 + CAR-T) cell culture fluid, after obtaining supernatant by ultracentrifugation, again by ultrafiltration cut-off purification is obtained.The present application is first isolated and identified from CD4 + CAR-T cell a new type of low-density extracellular vesicles (LD-EVs), the subtype is missed in traditional EV separation process, and the cognition to EV diversity is widened.The characteristics of LD-EVs are rich in sterol ester (especially cholesterin ester) by lipidomics etc., which is related to its low-density characteristics and potential membrane stability, signal transmission function, provides target for functional research and engineering modification.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

This invention discloses the preparation and application of a recombinant cholesterol esterase immobilized enzyme preparation. This invention will... Ophiostoma piceae Cholesterol esterase mutant gene ope-D136P Linked to pPICZαA plasmid, via signal peptide replacement and rDNA Gene insertion yielded the pEESB-3 plasmid; the protein disulfide isomerase gene was inserted. pdi The pPIC9K plasmid was ligated to obtain the pEESB-4 plasmid. This plasmid was electroporated into Pichia pastoris GS115, and after resistance selection and methanol-induced expression selection, recombinant Pichia pastoris engineered strains were obtained. Recombinant cholesterol esterase was obtained from this strain after methanol-induced expression. An aminated immobilization vector was prepared using APTES and TEOS as silane precursors. After grafting with 2,4-dihydroxyacetophenone and nickel ion chelation, the recombinant cholesterol esterase was immobilized to obtain an immobilized enzyme preparation. This immobilized enzyme preparation can catalyze the synthesis of stigmasterol ferulic acid ester from stigmasterol in a non-aqueous phase system, with a conversion rate of 33% (based on stigmasterol) or 32% (based on ferulic acid).